首页> 外文期刊>Stem Cell Reviews and Reports >Therapeutic Potential of Adult Bone Marrow Stem Cells in Liver Disease and Delivery Approaches
【24h】

Therapeutic Potential of Adult Bone Marrow Stem Cells in Liver Disease and Delivery Approaches

机译:成年骨髓干细胞在肝脏疾病中的治疗潜力及治疗方法

获取原文
获取原文并翻译 | 示例
           

摘要

Hematopoietic stem cells (HSCs) and mesenchymal stem cell (MSCs) are two main subtypes of bone marrow stem cells. Extensive studies have been carried out to investigate the therapeutic potential of BMSCs in liver disease. A number of animal and human studies demonstrated that either HSCs or MSCs could be applied to therapeutic purposes in certain liver diseases. The diseased liver may recruit migratory stem cells, particularly from the bone marrow, to generate hepatocyte-like cells either by transdifferentiation or cell fusion. Transplantation of BMSCs has therapeutic effects of restoration of liver mass and function, alleviation of fibrosis and correction of inherited liver diseases. There are still controversial results over the potential effects of BMSCs on liver diseases, and some of the discrepancies are thought to be lied in the differences of experimental protocols, differences in individual research laboratory, and the uncertainties of the techniques employed. Several potential approaches for BMSCs delivery in liver diseases have been proposed in animal studies and human trials. BMSCs can be delivered via intraportal vein, systemic infusion, intraperitoneal, intrahepatic, intrasplenic. The optimal stem cells delivery should be easy to perform, less invasive and traumatic, minimum side effects, and with high cells survival rate. In this review, we focus on the up-to-date evidence of therapeutic effects of BMSCs on liver disease, the characteristics of various delivery approaches, and the considerations for future studies.
机译:造血干细胞(HSC)和间充质干细胞(MSC)是骨髓干细胞的两个主要亚型。已经进行了广泛的研究以研究BMSC在肝脏疾病中的治疗潜力。许多动物和人类研究表明,HSC或MSC均可用于某些肝病的治疗目的。患病的肝脏可能会通过转分化或细胞融合来募集迁徙干细胞(特别是从骨髓中迁出)以生成肝细胞样细胞。骨髓间充质干细胞的移植具有恢复肝脏质量和功能,减轻纤维化和纠正遗传性肝病的治疗作用。关于骨髓间充质干细胞对肝脏疾病的潜在影响,仍存在争议的结果,一些差异被认为是由于实验方案的差异,各个研究实验室的差异以及所采用技术的不确定性。在动物研究和人体试验中已经提出了几种在肝脏疾病中递送BMSC的潜在方法。 BMSC可以通过门静脉,全身输注,腹膜内,肝内,脾内递送。最佳的干细胞递送应易于执行,具有较小的侵入性和创伤性,最小的副作用,并具有较高的细胞存活率。在这篇综述中,我们关注于BMSCs对肝脏疾病的治疗作用的最新证据,各种递送方法的特征以及对未来研究的考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号